STRO

Sutro Biopharma, Inc. NASDAQ

Healthcare ·Biotechnology ·US · sutrobio.com

$38.39

Mkt Cap $326.2M

52w Low $6.70 97.8% of range 52w High $39.10

50d MA $25.97 200d MA $14.21

P/E (TTM) -1.6x

EV/EBITDA -0.6x

P/B —

Debt/Equity -0.1x

ROE 144.3%

P/FCF -0.5x

RSI (14) —

ATR (14) —

Beta 1.31

50d MA $25.97

200d MA $14.21

Avg Volume 193.6K

About

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	1M%	Guide ▲★
Mar 23, 2026	AMC	-8.16	-5.29	+35.2%	21.33	+8.8%	+10.5%	+10.2%	+16.8%	+14.5%	+13.0%	+66.6%	—
Nov 6, 2025	AMC	-4.20	-6.70	-59.5%	9.42	-4.5%	-13.4%	-14.4%	-13.7%	-13.9%	-1.4%	-9.9%	—
Aug 7, 2025	AMC	-0.39	-0.14	+64.1%	8.00	+0.5%	+0.2%	-3.4%	-2.0%	-3.5%	-2.5%	+22.8%	—
May 8, 2025	AMC	-0.63	-0.91	-44.4%	9.58	+4.4%	-9.0%	-9.2%	-14.9%	-23.5%	-8.2%	-13.7%	—
Mar 13, 2025	AMC	-0.86	-0.89	-3.5%	12.50	-20.1%	-35.2%	-25.4%	-28.3%	-34.3%	-36.3%	-52.2%	—
Nov 13, 2024	AMC	-0.74	-0.59	+20.3%	39.60	-1.8%	-12.9%	-27.0%	-30.6%	-31.8%	-32.6%	-46.5%	—
Aug 13, 2024	AMC	-0.76	-0.59	+22.4%	32.20	+10.2%	+11.5%	+25.5%	+30.7%	+42.9%	+48.1%	+38.2%	—
May 13, 2024	AMC	-0.92	-0.95	-3.3%	42.30	-0.2%	+2.6%	-7.1%	-1.9%	-5.2%	+10.6%	-7.8%	—
Mar 25, 2024	AMC	-0.82	0.42	+151.2%	32.70	+17.4%	+27.8%	+50.8%	+72.8%	+63.0%	+55.7%	+6.1%	—
Nov 13, 2023	AMC	-0.76	-0.81	-6.6%	20.70	-0.5%	+14.5%	+18.8%	+13.5%	+30.0%	+33.8%	+89.9%	—
Aug 10, 2023	AMC	-0.73	-0.64	+12.3%	43.40	-2.8%	-1.8%	-1.2%	-1.6%	-7.6%	-3.0%	+6.0%	—
May 15, 2023	AMC	-0.83	-0.76	+8.4%	58.80	-3.9%	-2.6%	-2.2%	-10.0%	-8.0%	-9.7%	-9.2%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 30	Mizuho	Initiates	Outperform	$50	$35.39	$36.54	+3.2%	+3.5%	+0.6%	—	—	—
Apr 23	Citizens	Maintains	Market Outperform → Market Outperform	—	$35.53	$35.93	+1.1%	-2.0%	-6.2%	-5.5%	-2.4%	-0.4%
Apr 17	Citizens	Maintains	Market Outperform → Market Outperform	—	$29.35	$30.57	+4.2%	+7.5%	+17.8%	+17.0%	+21.1%	+18.7%
Mar 25	Deutsche Bank	Maintains	Buy → Buy	—	$23.57	$24.38	+3.4%	-0.3%	+5.7%	+3.6%	+2.2%	+5.7%
Mar 24	Wells Fargo	Upgrade	Equal Weight → Overweight	—	$21.33	$23.21	+8.8%	+10.5%	+10.2%	+16.8%	+14.5%	+13.0%
Mar 24	HC Wainwright & Co.	Upgrade	Neutral → Buy	—	$21.33	$23.21	+8.8%	+10.5%	+10.2%	+16.8%	+14.5%	+13.0%
Jan 20	Citizens	Upgrade	Market Perform → Market Outperform	—	$13.82	$14.19	+2.7%	+8.0%	+14.3%	+18.1%	+8.9%	+13.2%
Dec 22	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$9.98	$9.83	-1.5%	+3.9%	+4.0%	+7.7%	+15.1%	+11.2%
Aug 12	Wells Fargo	Maintains	Equal Weight → Equal Weight	—	$7.73	$7.65	-1.0%	+1.4%	-0.1%	+0.9%	+13.6%	+18.4%
Jun 16	Piper Sandler	Upgrade	Neutral → Overweight	—	$7.99	$8.70	+8.9%	+10.3%	-1.1%	-0.6%	+0.3%	+0.0%
May 19	BofA Securities	Maintains	Underperform → Underperform	—	$9.12	$9.09	-0.3%	-3.7%	-1.3%	-8.1%	-1.0%	+0.9%
Apr 29	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$8.97	$8.70	-3.0%	-2.5%	+17.1%	+19.3%	+22.6%	+17.1%
Mar 17	HC Wainwright & Co.	Downgrade	Buy → Neutral	—	$8.10	$8.17	+0.9%	+15.1%	+10.6%	+1.4%	-1.7%	-5.3%
Mar 14	BofA Securities	Downgrade	Buy → Underperform	—	$12.50	$9.99	-20.1%	-35.2%	-25.4%	-28.3%	-34.3%	-36.3%
Mar 14	Wedbush	Downgrade	Outperform → Neutral	—	$12.50	$9.99	-20.1%	-35.2%	-25.4%	-28.3%	-34.3%	-36.3%
Mar 14	Citizens Capital Markets	Downgrade	Market Outperform → Market Perform	—	$12.50	$9.99	-20.1%	-35.2%	-25.4%	-28.3%	-34.3%	-36.3%
Dec 11	Wells Fargo	Maintains	Equal Weight → Equal Weight	—	$23.50	$23.80	+1.3%	+4.3%	-6.4%	-9.8%	-11.9%	-11.1%
Dec 11	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$23.50	$23.80	+1.3%	+4.3%	-6.4%	-9.8%	-11.9%	-11.1%
Nov 18	HC Wainwright & Co.	Maintains	Buy → Buy	—	$28.90	$29.10	+0.7%	-4.8%	-6.6%	-7.6%	-12.5%	-13.1%
Oct 11	Piper Sandler	Maintains	Overweight → Overweight	—	$33.10	$33.50	+1.2%	+14.5%	+15.7%	+15.7%	+13.9%	+12.1%
Oct 11	HC Wainwright & Co.	Maintains	Buy → Buy	—	$33.10	$33.50	+1.2%	+14.5%	+15.7%	+15.7%	+13.9%	+12.1%
Sep 16	HC Wainwright & Co.	Maintains	Buy → Buy	—	$45.00	$44.60	-0.9%	-17.8%	-10.9%	-12.2%	-12.9%	-16.2%
Sep 16	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$45.00	$44.60	-0.9%	-17.8%	-10.9%	-12.2%	-12.9%	-16.2%
Aug 16	Truist	Maintains	Buy → Buy	—	$40.40	$40.40	+0.0%	+4.2%	+13.9%	+18.1%	+12.9%	+12.6%
Aug 14	HC Wainwright & Co.	Maintains	Buy → Buy	—	$32.20	$35.50	+10.2%	+11.5%	+25.5%	+30.7%	+42.9%	+48.1%
May 15	Oppenheimer	Maintains	Outperform → Outperform	—	$43.40	$43.40	+0.0%	-9.4%	-4.4%	-7.6%	+7.8%	+4.6%
May 14	Wedbush	Maintains	Outperform → Outperform	—	$42.30	$42.20	-0.2%	+2.6%	-7.1%	-1.9%	-5.2%	+10.6%
May 14	HC Wainwright & Co.	Maintains	Buy → Buy	—	$42.30	$42.20	-0.2%	+2.6%	-7.1%	-1.9%	-5.2%	+10.6%
Apr 3	Piper Sandler	Maintains	Overweight → Overweight	—	$50.90	$51.90	+2.0%	+0.0%	-3.3%	-4.1%	-6.9%	-13.8%
Apr 3	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$50.90	$51.90	+2.0%	+0.0%	-3.3%	-4.1%	-6.9%	-13.8%
Apr 3	Oppenheimer	Maintains	Outperform → Outperform	—	$50.90	$51.90	+2.0%	+0.0%	-3.3%	-4.1%	-6.9%	-13.8%
Apr 3	Truist	Maintains	Buy → Buy	—	$50.90	$51.90	+2.0%	+0.0%	-3.3%	-4.1%	-6.9%	-13.8%
Mar 28	Oppenheimer	Maintains	Outperform → Outperform	—	$49.30	$49.70	+0.8%	+14.6%	+8.1%	+3.2%	+3.2%	-0.2%
Mar 27	Oppenheimer	Maintains	Outperform → Outperform	—	$41.80	$42.60	+1.9%	+17.9%	+35.2%	+27.5%	+21.8%	+21.8%
Mar 26	Wedbush	Maintains	Outperform → Outperform	—	$32.70	$38.40	+17.4%	+27.8%	+50.8%	+72.8%	+63.0%	+55.7%
Mar 26	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$32.70	$38.40	+17.4%	+27.8%	+50.8%	+72.8%	+63.0%	+55.7%
Mar 26	HC Wainwright & Co.	Maintains	Buy → Buy	—	$32.70	$38.40	+17.4%	+27.8%	+50.8%	+72.8%	+63.0%	+55.7%
Nov 15	Piper Sandler	Maintains	Overweight → Overweight	—	$23.70	$23.40	-1.3%	+3.8%	-0.8%	+13.5%	+16.9%	+13.5%
Nov 14	HC Wainwright & Co.	Maintains	Buy → Buy	—	$20.70	$20.60	-0.5%	+14.5%	+18.8%	+13.5%	+30.0%	+33.8%
Oct 23	Wedbush	Maintains	Outperform → Outperform	—	$31.90	$31.90	+0.0%	-7.5%	-12.9%	-11.6%	-14.7%	-19.7%
Sep 6	Truist	Maintains	Buy → Buy	—	$44.00	$44.00	+0.0%	+2.7%	+3.2%	+2.7%	+4.5%	+3.2%
Aug 14	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$42.60	$42.10	-1.2%	+0.7%	+0.2%	-5.9%	-1.2%	+4.9%
Aug 11	Wedbush	Maintains	Outperform → Outperform	—	$43.40	$42.20	-2.8%	-1.8%	-1.2%	-1.6%	-7.6%	-3.0%
Aug 11	HC Wainwright & Co.	Maintains	Buy → Buy	—	$43.40	$42.20	-2.8%	-1.8%	-1.2%	-1.6%	-7.6%	-3.0%
Jun 27	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$52.50	$52.60	+0.2%	-3.0%	-5.0%	-11.4%	-11.4%	-10.9%
May 17	JMP Securities	Maintains	Market Outperform → Outperform	—	$57.30	$57.10	-0.3%	+0.3%	-7.7%	-5.6%	-7.3%	-7.7%
May 17	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$57.30	$57.10	-0.3%	+0.3%	-7.7%	-5.6%	-7.3%	-7.7%
May 16	HC Wainwright & Co.	Maintains	Buy → Buy	—	$58.80	$56.50	-3.9%	-2.6%	-2.2%	-10.0%	-8.0%	-9.7%
Apr 3	JMP Securities	Maintains	Outperform → Outperform	—	$46.20	$47.00	+1.7%	+2.2%	-6.7%	-6.3%	-0.6%	-6.5%
Mar 31	Wedbush	Maintains	Outperform → Outperform	—	$44.80	$44.40	-0.9%	+3.1%	+5.4%	-3.8%	-3.3%	+2.5%

Recent Filings

8-K · 1.02 !! High

Unknown — 8-K 1.02: Material Agreement Terminated

The termination of a material agreement signals potential operational disruption or loss of revenue/partnership benefits, requiring investors to assess impact on earnings guidance and competitive positioning.

Mar 23

8-K

Sutro Biopharma, Inc. -- 8-K Filing

Sutro Biopharma secured funding through an offering to support R&D, clinical development, manufacturing, and potential acquisitions for its biopharmaceutical pipeline.

Feb 10

Data updated apr 27, 2026 3:20am · Source: massive.com